Showing 1,021 - 1,040 results of 6,597 for search 'Hejaz~', query time: 3.39s Refine Results
  1. 1021
  2. 1022
  3. 1023
  4. 1024
  5. 1025
  6. 1026
  7. 1027

    Slow Metabolism–Driven Amplification of Hepatic PPARγ Agonism Mediates Benzbromarone‐Induced Obesity‐Specific Liver Injury by Guanting Li, Yourong Hu, Han Zhao, Ziyu Peng, Xin Shang, Jia Zhang, Kunxin Xie, Meiwei Li, Xiaohang Zhou, Qinyao Zhou, Kai Li, Fang Zhou, Heyao Wang, Zhijian Xu, Jiali Liu, Peng Sun

    Published 2025-01-01
    “…This reduction leads to prolonged retention of BBR, subsequently resulting in chronic and sustained hepatic PPARγ agonism. This study demonstrates that a slow metabolism‐driven amplification of hepatic PPARγ agonism mediates BBR‐induced obesity‐specific hepatic steatosis and subsequent DILI, which also emphasizes the importance of the reduced hepatic drug metabolism capacity in patients with obesity or pre‐existing NAFLD in both clinical practice and drug discovery processes.…”
    Get full text
    Article
  8. 1028
  9. 1029

    Primary Hepatic Lymphoma Presenting as an Acute Abdomen in a Young Female Patient: A Case Report and Literature Review by Walid E. Abdelrahim, Kamal E. Mohamed, Salwa O. Mekki, Eltaib A. Saad

    Published 2019-01-01
    “…We report a rare case of primary hepatic lymphoma (PHL) in a hepatitis B virus- (HBV-) infected young female patient who presented with right upper abdominal pain, nausea, and vomiting for a few days. …”
    Get full text
    Article
  10. 1030
  11. 1031

    A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C by Masafumi Komatsu, Tsuyoshi Ono, Ko Nakajima, Itaru Toyoshima, Mitsuro Chiba, Osamu Masamune, Shunji Ohkubo, Tsukasa Yoshida, Hitoshi Yagisawa, Kanji Komatsu, Hideki Wakamatsu, Nobuo Yamada, Hiroyuki Watanabe, Tsuyoshi Mukojima, Mitsuo Goto

    Published 1997-01-01
    “…Sixty-one chronic hepatitis C patients were randomly assigned to receive either 6x106 or 9x106 U of recombinant interferon-alpha-2a (IFNα-2a) six days a week for the first two weeks of treatment, followed in both cases by 6x106 U three days a week for the next 22 weeks. …”
    Get full text
    Article
  12. 1032

    Circulating IL-1β, IL-17, and IP-10 as Potential Predictors of Hepatitis B Virus Infection Prognosis by Zhenzhen Su, Jie Chen, Junlong Zhang, Yunfei An, Yun Liao, Xiaojuan Wu, Chuanmin Tao, Lanlan Wang, Bei Cai

    Published 2022-01-01
    “…Circulating cytokines and chemokines play critical roles in hepatitis B virus (HBV) infection. Here, we explored the effects of proinflammatory and anti-inflammatory effector molecules on HBV progression, e antigen seroconversion, and liver function. …”
    Get full text
    Article
  13. 1033
  14. 1034
  15. 1035
  16. 1036
  17. 1037
  18. 1038

    Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study by Mengzhi Cai, Yanli Hao, Jianxin Zhong, Wei Yao, Xia Cao, Guifang Gu, Gang Qin

    Published 2019-01-01
    “…To investigate the efficacy of telbivudine (LdT) in blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV) during late pregnancy. Methods. …”
    Get full text
    Article
  19. 1039
  20. 1040

    Animal-based evidence supports protective activity of bioengineered silver and gold nanomaterials on hepatic and renal function profile parameters by Hamed Barabadi, Hesam Noqani, Maha Soltani, Ayeh Sabbagh Kashani

    Published 2025-01-01
    “…This review presents the novelty of bioengineered NPs as potential therapeutic agents for hepatic and renal protection while highlighting the need for further research into their pharmacokinetics and pharmacodynamics to advance clinical translation.…”
    Get full text
    Article